Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.
Foot-and-mouth disease remains a major plague of livestock and outbreaks are often economically catastrophic. Current inactivated virus vaccines require expensive high containment facilities for their production and maintenance of a cold-chain for their activity. We have addressed both of these majo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2013
|
| _version_ | 1826284460034752512 |
|---|---|
| author | Porta, C Kotecha, A Burman, A Jackson, T Ren, J Loureiro, S Jones, I Fry, E Stuart, D Charleston, B |
| author_facet | Porta, C Kotecha, A Burman, A Jackson, T Ren, J Loureiro, S Jones, I Fry, E Stuart, D Charleston, B |
| author_sort | Porta, C |
| collection | OXFORD |
| description | Foot-and-mouth disease remains a major plague of livestock and outbreaks are often economically catastrophic. Current inactivated virus vaccines require expensive high containment facilities for their production and maintenance of a cold-chain for their activity. We have addressed both of these major drawbacks. Firstly we have developed methods to efficiently express recombinant empty capsids. Expression constructs aimed at lowering the levels and activity of the viral protease required for the cleavage of the capsid protein precursor were used; this enabled the synthesis of empty A-serotype capsids in eukaryotic cells at levels potentially attractive to industry using both vaccinia virus and baculovirus driven expression. Secondly we have enhanced capsid stability by incorporating a rationally designed mutation, and shown by X-ray crystallography that stabilised and wild-type empty capsids have essentially the same structure as intact virus. Cattle vaccinated with recombinant capsids showed sustained virus neutralisation titres and protection from challenge 34 weeks after immunization. This approach to vaccine antigen production has several potential advantages over current technologies by reducing production costs, eliminating the risk of infectivity and enhancing the temperature stability of the product. Similar strategies that will optimize host cell viability during expression of a foreign toxic gene and/or improve capsid stability could allow the production of safe vaccines for other pathogenic picornaviruses of humans and animals. |
| first_indexed | 2024-03-07T01:14:09Z |
| format | Journal article |
| id | oxford-uuid:8e130b46-8e02-49d4-86b3-fa7dd99c764b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:14:09Z |
| publishDate | 2013 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:8e130b46-8e02-49d4-86b3-fa7dd99c764b2022-03-26T22:55:13ZRational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8e130b46-8e02-49d4-86b3-fa7dd99c764bEnglishSymplectic Elements at OxfordPublic Library of Science2013Porta, CKotecha, ABurman, AJackson, TRen, JLoureiro, SJones, IFry, EStuart, DCharleston, BFoot-and-mouth disease remains a major plague of livestock and outbreaks are often economically catastrophic. Current inactivated virus vaccines require expensive high containment facilities for their production and maintenance of a cold-chain for their activity. We have addressed both of these major drawbacks. Firstly we have developed methods to efficiently express recombinant empty capsids. Expression constructs aimed at lowering the levels and activity of the viral protease required for the cleavage of the capsid protein precursor were used; this enabled the synthesis of empty A-serotype capsids in eukaryotic cells at levels potentially attractive to industry using both vaccinia virus and baculovirus driven expression. Secondly we have enhanced capsid stability by incorporating a rationally designed mutation, and shown by X-ray crystallography that stabilised and wild-type empty capsids have essentially the same structure as intact virus. Cattle vaccinated with recombinant capsids showed sustained virus neutralisation titres and protection from challenge 34 weeks after immunization. This approach to vaccine antigen production has several potential advantages over current technologies by reducing production costs, eliminating the risk of infectivity and enhancing the temperature stability of the product. Similar strategies that will optimize host cell viability during expression of a foreign toxic gene and/or improve capsid stability could allow the production of safe vaccines for other pathogenic picornaviruses of humans and animals. |
| spellingShingle | Porta, C Kotecha, A Burman, A Jackson, T Ren, J Loureiro, S Jones, I Fry, E Stuart, D Charleston, B Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title | Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title_full | Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title_fullStr | Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title_full_unstemmed | Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title_short | Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. |
| title_sort | rational engineering of recombinant picornavirus capsids to produce safe protective vaccine antigen |
| work_keys_str_mv | AT portac rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT kotechaa rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT burmana rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT jacksont rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT renj rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT loureiros rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT jonesi rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT frye rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT stuartd rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen AT charlestonb rationalengineeringofrecombinantpicornaviruscapsidstoproducesafeprotectivevaccineantigen |